3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Arthritis, Psoriatic
1
Interventions
Carboplatin
97
Cisplatin
94
pembrolizumab
90
Gemcitabine
81
Paclitaxel
80
Docetaxel
73
Capecitabine
64
Specimen Handling
53
Oxaliplatin
53
Fluorouracil
52
Magnetic Resonance Spectroscopy
51
Bevacizumab
49
Radiotherapy
48
Dexamethasone
45
Cyclophosphamide
44
Leucovorin
39
Drug Therapy
39
Irinotecan
37
Doxorubicin
36
Pemetrexed
34
Injections
30
Trastuzumab
28
Vincristine
27
Rituximab
27
Radiosurgery
25
Prednisone
25
Etoposide
25
130-nm albumin-bound paclitaxel
25
Radiation
24
Letrozole
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
risankizumab
×
Clear all
NCT06641089
2026-06-12
IZAR-2
MoonLake Immunotherapeutics AG
Phase 3
Recruiting
600 enrolled